	US 11,779,612 B2
	Engineered immunostimulatory bacterial strains and uses thereof
Christopher D. Thanos, Tiburon, CA (US); Laura Hix Glickman, Oakland, CA (US); Justin Skoble, Berkeley, CA (US); and Alexandre Charles Michel Iannello, Oakland, CA (US)
Assigned to ACTYM THERAPEUTICS, INC., Berkeley, CA (US)
Filed by Actym Therapeutics, Inc., Berkeley, CA (US)
Filed on Jul. 23, 2019, as Appl. No. 16/520,155.
Application 16/520,155 is a continuation of application No. PCT/US2019/041489, filed on Jul. 11, 2019.
Claims priority of provisional application 62/828,990, filed on Apr. 3, 2019.
Claims priority of provisional application 62/789,983, filed on Jan. 8, 2019.
Prior Publication US 2020/0215123 A1, Jul. 9, 2020
Int. Cl. A61K 35/74 (2015.01); A61K 39/112 (2006.01); C07K 14/52 (2006.01); C07K 16/24 (2006.01); C12N 15/74 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 1/20 (2006.01); C12R 1/42 (2006.01)

CPC A61K 35/74 (2013.01) [A61K 39/0275 (2013.01); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C07K 16/248 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 1/205 (2021.05); C12N 15/74 (2013.01); A61K 45/06 (2013.01); C12R 2001/42 (2021.05)]

60 Claims

1. A method of treatment of cancer that comprises a solid tumor or a hematological malignancy in a subject, comprising administering an immunostimulatory bacterium, wherein:

the immunostimulatory bacterium comprises a plasmid that encodes an anti-cancer therapeutic product;

the genome of the immunostimulatory bacterium is modified so that, compared to the bacterium without the genome modifications, the bacterium has increased ability to infect tumor-resident immune cells, and has reduced ability to infect or does not infect epithelial cells; and

the anti-cancer therapeutic product is expressed under the control of one or more eukaryotic regulatory sequences, whereby the product is expressed in the tumor-resident immune cells in the subject.